71 active not recruiting. 71 Phase 2, 19 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 71 | Active not recruiting 71 |
| Phase 1 | 19 | Active not recruiting 19 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers Pirtobrutinib - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Active not recruiting | Eli Lilly and Company | 13 | 2025-08-07 | 2026-04-17 |
| A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia Sonrotoclax, Zanubrutinib - Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | BeOne Medicines | 94 | 2024-11-14 | 2026-07-09 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period Venetoclax, cBTKi Monotherapy - Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | Genentech, Inc. | 118 | 2024-08-09 | 2026-09-28 |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia Ibrutinib, Venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 333 | 2024-05-30 | 2026-09-25 |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT) - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 313 | 2023-12-08 | 2026-08-17 |
| A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies GNC-035 - Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 3 | 2023-08-16 | 2025-09-26 |
| Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL VenObi+Ven or VenObi+VenZan - High Risk CLL, Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 78 | 2023-07-21 | 2026-03-17 |
| Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 26 | 2023-05-18 | 2026-10-01 |
| Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 50 | 2023-05-08 | 2026-02-25 |
| Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Mayo Clinic | 72 | 2023-01-31 | 2026-02-12 |
| Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Acalabrutinib, Durvalumab, Venetoclax - Chronic Lymphocytic Leukemia, Richter Syndrome | Phase 2 | Active not recruiting | Mayo Clinic | 27 | 2023-01-05 | 2026-10-05 |
| Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma BGB-11417 - Leukemia, Lymphoma | Phase 2 | Active not recruiting | BeiGene | 100 | 2022-10-25 | 2026-03-04 |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) Zilovertamab vedotin, Nemtabrutinib - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 189 | 2022-07-21 | 2026-08-21 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Busulfan, Fludarabine, Total-body irradiation - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 300 | 2021-09-30 | 2026-03-18 |
| Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation Polatuzumab Vedotin, Rituximab, Etoposide - Richter Syndrome, Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 20 | 2021-09-24 | 2026-09-25 |
| A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL Acalabrutinib, Obinutuzumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 55 | 2021-05-21 | 2026-06-04 |
| Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia Acalabrutinib - Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 4 | 2021-03-16 | 2026-05-06 |
| Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Acalabrutinib, Umbralisib, Ublituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Jennifer R. Brown, MD, PhD | 29 | 2020-12-15 | 2026-02-25 |
| The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2020-12-03 | 2026-07-07 |
Showing 20 of 71. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (66) · Leukemia (14) · Lymphoma (9) · Lymphoma, Mantle-Cell (9) · Lymphoma, Non-Hodgkin (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Follicular (7) · Lymphoma, Large B-Cell, Diffuse (7) · Leukemia, Lymphoid (6) · Leukemia, Myeloid, Acute (6) · Lymphoproliferative Disorders (6) · Myelodysplastic Syndromes (6) · Recurrence (6)
Hemic and Lymphatic Diseases (71) · Disease Attributes (68) · Immune System Diseases (68) · Lymphatic Diseases (68) · Neoplasms by Histologic Type (68) · Pathologic Processes (68) · Pathological Conditions, Signs and Symptoms (68) · Chronic Disease (67) · Hematologic Diseases (67) · Immunoproliferative Disorders (67) · Neoplasms (66) · Leukemia, Lymphoid (65) · Lymphoproliferative Disorders (65) · Leukemia (57)
venetoclax (22) · Cyclophosphamide (16) · ibrutinib (15) · acalabrutinib (13) · Rituximab (11) · obinutuzumab (11) · fludarabine phosphate (10) · fludarabine (8) · zanubrutinib (6) · Biopsy (4) · Doxorubicin (4) · Lenalidomide (4) · Melphalan (4) · Mesna (4) · Mycophenolic Acid (4)
M.D. Anderson Cancer Center (10) · City of Hope Medical Center (6) · Memorial Sloan Kettering Cancer Center (5) · Acerta Pharma BV (3) · Dana-Farber Cancer Institute (3) · Genmab (3) · Center for International Blood and Marrow Transplant Research (2) · French Innovative Leukemia Organisation (2) · Mayo Clinic (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Weill Medical College of Cornell University (2) · AbbVie (1) · Allogene Therapeutics (1) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · AstraZeneca (1)
United States (59) · France (8) · Italy (8) · Spain (8) · China (7) · Australia (6) · United Kingdom (6) · Canada (5) · Germany (5) · Poland (5) · Czechia (4) · Israel (4) · Brazil (3) · Japan (3) · Sweden (3)
Jan A Burger (3) · Meghan Thompson, MD (3) · Nitin Jain (3) · Andy Itsara, M.D. (2) · John Allan, M.D. (2) · Kerry Rogers, MD (2) · Matthew Davids, MD (2) · Steven Devine, MD (2) · Aimee C. Talleur, MD (1) · Ajay K. Gopal (1) · Alessandra Ferrajoli (1)
PMID 27503501, PMID 28714866, PMID 34398557, PMID 34608724, PMID 42411504, PMID 42541678, PMID 24659631, PMID 24699307, PMID 25555420, PMID 26182309, PMID 26337493, PMID 26430171, PMID 26641137, PMID 26982511, PMID 27601462, PMID 27760761, PMID 28049639, PMID 28089238, PMID 29358183, PMID 29483101, PMID 30111609, PMID 30530801, PMID 30938714, PMID 31076409, PMID 31088809, PMID 31141631, PMID 31208944, PMID 31876911, PMID 32040960, PMID 32795224, PMID 33206936, PMID 33730844, PMID 33963002, PMID 34110383, PMID 34508654, PMID 34515338, PMID 34534514, PMID 34699592, PMID 34735860, PMID 34826411, PMID 34865212, PMID 35446934, PMID 35610089, PMID 36385536, PMID 36442911, PMID 36548927, PMID 37227160, PMID 37295445, PMID 37930156, PMID 38151388
2023 (4), P30CA033572 (4), 2014 (1), 2015 (1), 2017 (1), 2018 (1), N01CM00070 (1), N01CM62207 (1), P01CA095426 (1), P30CA016058 (1), P50CA140158 (1), R01CA077544 (1), R01CA266298 (1)